Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion

Novartis's acquisition of Excellergy signifies a strategic move to enhance its immunology portfolio with innovative allergy treatments, potentially accelerating the development of new therapies. This deal highlights the growing importance of allergy and immunology research within the biotech industry. For consumers, it promises the possibility of more effective and targeted allergy medications in the future.

• Novartis is investing heavily in allergy and immunology research.
• The acquisition could lead to new, innovative allergy treatments.
• This move underscores the biotech industry's focus on personalized medicine.